AdBoards

A leading diagnostics player wanted an assessment of the current and future carrier screening landscape, primarily in the U.S., to guide their product development strategy

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy

A leader in synthetic oligonucleotide manufacturing wanted to assess the total market size and opportunity

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings